REZUROCK

At a glance

Key dates

1. Approval

   FDA approval date of this drug product.

   Jul 16, 2021

   5 yr ago

2. Today

3. Exclusivity ends · NCE

   New chemical entity exclusivity (5 years)

   Jul 16, 2026

   in 27 d

4. Exclusivity ends · ODE-362

   Orphan-drug exclusivity (7 years)

   Jul 16, 2028

   in 2 yr 1 mo

5. Patent 10183931 expires

   Listed method-of-use patent (U-4260) expiration.

   Oct 07, 2033

   in 7 yr 5 mo

6. Patent 10183931 expires

   Listed method-of-use patent (U-3246) expiration.

   Oct 07, 2033

   in 7 yr 5 mo

7. Patent 10696660 expires

   Listed method-of-use patent (U-4260) expiration.

   Oct 07, 2033

   in 7 yr 5 mo

8. Patent 10696660 expires

   Listed method-of-use patent (U-3246) expiration.

   Oct 07, 2033

   in 7 yr 5 mo

9. Patent 8357693 expires

   Listed drug substance patent expiration.

   Jun 20, 2034

   in 8 yr 1 mo

10. Patent 11311541 expires

    Listed method-of-use patent (U-3369) expiration.

    Apr 09, 2035

    in 8 yr 11 mo

11. Patent 12097202 expires

    Listed method-of-use patent (U-4014) expiration.

    Jul 14, 2042

    in 16 yr 4 mo

Pharmaceutical detail

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (2)

• NCENew chemical entity exclusivity (5 years)

  Jul 16, 2026

  in 27 d

• ODE-362Orphan-drug exclusivity (7 years)

  Jul 16, 2028

  in 2 yr 1 mo

Listed patents (7)